US Patent 9790180 Piperidine derivatives as HDAC1/2 inhibitors
Patent 9790180 was granted and assigned to Regenacy Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
00
Current Assignee
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+212 characters)
Article
Patent abstract
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09790180 Piperidine derivatives as HDAC1/2 inhibitors US Patent 9790180 Piperidine derivatives as HDAC1/2 inhibitors
Infobox
Patent Number
0979018000
Patent Number
979018000
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
097901800
Date of Patent
October 17, 2017
0Patent Application Number
149665560
Date Filed
December 11, 2015
0Patent Primary Examiner
Edits on 5 Oct, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
097901800
Date of Patent
October 17, 2017
0Patent Application Number
149665560
Date Filed
December 11, 2015
0Patent Primary Examiner
Edits on 15 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09790180 Piperidine derivatives as HDAC1/2 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09790180
Date of patent
October 17, 2017
Patent application number
14966556
Date Filed
December 11, 2015
Patent primary examiner
Find more entities like US Patent 9790180 Piperidine derivatives as HDAC1/2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
